https://www.selleckchem.com/pr....oducts/propionyl-l-c
We report a case of accessory breast cancer in the axillary region with some review of the literature. The clinical efficacy of nivolumab has been shown as a third-line treatment for advanced gastric cancer; however, nivolumab sometimes causes immune-related adverse events(irAEs). We retrospectively examined the clinical features and influence on treatment in cases of irAEs after nivolumab treatment. We retrospectively examined 43 patients who received nivolumab treatment at our institution between October 20
Like
Comment
Share
